1. Home
  2. CURR vs CABA Comparison

CURR vs CABA Comparison

Compare CURR & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CURR
  • CABA
  • Stock Information
  • Founded
  • CURR 2013
  • CABA 2017
  • Country
  • CURR Singapore
  • CABA United States
  • Employees
  • CURR N/A
  • CABA N/A
  • Industry
  • CURR Business Services
  • CABA Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CURR Consumer Discretionary
  • CABA Health Care
  • Exchange
  • CURR Nasdaq
  • CABA Nasdaq
  • Market Cap
  • CURR 151.4M
  • CABA 149.3M
  • IPO Year
  • CURR N/A
  • CABA 2019
  • Fundamental
  • Price
  • CURR $1.70
  • CABA $1.71
  • Analyst Decision
  • CURR Strong Buy
  • CABA Strong Buy
  • Analyst Count
  • CURR 1
  • CABA 7
  • Target Price
  • CURR $3.50
  • CABA $14.29
  • AVG Volume (30 Days)
  • CURR 591.8K
  • CABA 1.4M
  • Earning Date
  • CURR 08-04-2025
  • CABA 08-07-2025
  • Dividend Yield
  • CURR N/A
  • CABA N/A
  • EPS Growth
  • CURR N/A
  • CABA N/A
  • EPS
  • CURR N/A
  • CABA N/A
  • Revenue
  • CURR $41,092,419.00
  • CABA N/A
  • Revenue This Year
  • CURR N/A
  • CABA N/A
  • Revenue Next Year
  • CURR $21.53
  • CABA N/A
  • P/E Ratio
  • CURR N/A
  • CABA N/A
  • Revenue Growth
  • CURR N/A
  • CABA N/A
  • 52 Week Low
  • CURR $0.33
  • CABA $0.99
  • 52 Week High
  • CURR $7.08
  • CABA $6.26
  • Technical
  • Relative Strength Index (RSI)
  • CURR N/A
  • CABA 57.04
  • Support Level
  • CURR N/A
  • CABA $1.26
  • Resistance Level
  • CURR N/A
  • CABA $1.75
  • Average True Range (ATR)
  • CURR 0.00
  • CABA 0.13
  • MACD
  • CURR 0.00
  • CABA 0.03
  • Stochastic Oscillator
  • CURR 0.00
  • CABA 91.84

About CURR Currenc Group Inc. Ordinary Shares

Currenc Group Inc is a fintech pioneer dedicated to transforming financial services through artificial intelligence (AI). It empowers financial institutions with comprehensive AI solutions, including the SEAMLESS AI Call Centre and other AI-powered tools designed to reduce costs, increase efficiency, and boost customer satisfaction. The Company's digital remittance platform also enables e-wallets, remittance companies, and corporations to provide real-time, 24/7 payment services, advancing financial access across underserved communities. It generates the majority of its geographic revenue from Malaysia.

About CABA Cabaletta Bio Inc.

Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Share on Social Networks: